ISRCTN03554974已完成3 期
Efficacy and safety of agomelatine (25 mg/day with potential blinded adjustment to 50 mg/day) for 12 weeks in non-depressed out-patients with Generalised Anxiety Disorder
Institut de Recherches Internationales Servier (France)0 个研究点目标入组 390 人开始时间: 2010年7月5日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 390
研究概览
简要总结
2014 results in: http://www.ncbi.nlm.nih.gov/pubmed/24569045
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Out-patients of both genders aged between 18 (or legal majority) and 65 years of age (inclusive)
- •2. Fulfilling American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition-Text Revision (DSM-IV-TR) criteria for GAD
排除标准
- •1. Patients meeting DSM-IV-TR current diagnosis of psychiatric disorder other than GAD within 6 months prior to selection
- •2. Women of childbearing potential without effective contraception as well as pregnant or breastfeeding women
- •3. Any relevant clinical abnormality detected during physical examinations, ECG or laboratory tests likely to interfere with the study conduct or evaluations
研究者
相似试验
已完成
3 期
Efficacy and safety of agomelatine (25 mg/day with potential adjustment to 50 mg) given orally for eight weeks in out-patients with severe major depressive disorder: a randomised double-blind, parallel groups, international study versus selective serotonin reuptake inhibitor (SSRI) with a double-blind extension period of 16 weeksMajor depressive disorderMental and Behavioural DisordersDepressive episodeISRCTN19313268Institut de Recherches Internationales Servier (France)500
已完成
不适用
Efficacy of agomelatine given orally on the quality of remission in elderly depressed patients, after a 12-week treatment period. A randomised, double-blind, flexible-dose international multicentre study with parallel groups versus SSRI drug. Twelve-week treatment plus optional continuation for 12 weeks.ISRCTN68222771Institut de Recherches Internationales Servier (France)400
已完成
3 期
Efficacy of agomelatine given orally on rest/activity circadian rhythms in outpatients with major depressive disorder: a randomised, double-blind international study with parallel groups versus Selective Serotonin Reuptake Inhibitor (SSRI). Six-week treatment plus optional continuation for 18 weeks.Major depressive disorderMental and Behavioural DisordersDepressionISRCTN49376288Institut de Recherches Internationales Servier (France)300
已完成
不适用
Efficacy and safety of agomelatine (25-50 mg/day) for 12 weeks in patients with Generalized Anxiety DisorderGeneralized Anxiety DisorderMental and Behavioural DisordersGeneralized anxiety disorderISRCTN75061806Institut de Recherches Internationales Servier (France)510
进行中（未招募）
不适用
Efficacy of agomelatine 25 mg/day (with possible increase to 50 mg/day after 8 weeks of treatment) given orally during 16 weeks in patients with Obsessive-Compulsive Disorder. A randomised, double-blind, placebo-controlled, parallel groups, international study. - NDMedDRA version: 12.1Level: LLTClassification code 10029898Term: Obsessive-compulsive disorderObsessive-compulsive disorderEUCTR2009-016713-20-ITINSTITUT DE RECHERCHES INTERNATIONALES SERVIER80